A068270 Stock Overview
Develops and produces drugs based on proteins for the treatment of oncology in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celltrion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩204,500.00 |
| 52 Week High | ₩241,000.00 |
| 52 Week Low | ₩131,000.00 |
| Beta | 0.23 |
| 11 Month Change | 2.25% |
| 3 Month Change | 13.05% |
| 1 Year Change | 41.62% |
| 33 Year Change | -25.45% |
| 5 Year Change | 48.46% |
| Change since IPO | 1,957.83% |
Recent News & Updates
Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden
Jun 26
Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)
May 22Recent updates
Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden
Jun 26Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)
May 22Celltrion, Inc. (KRX:068270) Not Flying Under The Radar
Apr 30Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues
Mar 25We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt
Mar 19Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock
May 05Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)
Mar 25Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like
Mar 15Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?
Feb 24Celltrion (KRX:068270) Has A Rock Solid Balance Sheet
Feb 03Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?
Jan 13
Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?
Dec 23Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?
Dec 02Shareholder Returns
| A068270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.5% | 0.9% | -0.2% |
| 1Y | 41.6% | 38.9% | 4.1% |
Return vs Industry: A068270 exceeded the KR Biotechs industry which returned 38.9% over the past year.
Return vs Market: A068270 exceeded the KR Market which returned 4.1% over the past year.
Price Volatility
| A068270 volatility | |
|---|---|
| A068270 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A068270 has not had significant price volatility in the past 3 months.
Volatility Over Time: A068270's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,391 | Hyong-Gi Kim | www.celltrion.com |
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis.
Celltrion, Inc. Fundamentals Summary
| A068270 fundamental statistics | |
|---|---|
| Market cap | ₩41.79t |
| Earnings (TTM) | ₩323.33b |
| Revenue (TTM) | ₩2.67t |
130.5x
P/E Ratio15.8x
P/S RatioIs A068270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A068270 income statement (TTM) | |
|---|---|
| Revenue | ₩2.67t |
| Cost of Revenue | ₩1.48t |
| Gross Profit | ₩1.19t |
| Other Expenses | ₩862.69b |
| Earnings | ₩323.33b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.57k |
| Gross Margin | 44.48% |
| Net Profit Margin | 12.13% |
| Debt/Equity Ratio | 12.6% |
How did A068270 perform over the long term?
See historical performance and comparison